Teva Canada Ltd v Pfizer Canada Inc
Supreme Court of Canada case / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Teva Canada Ltd v Pfizer Canada Inc?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Teva Canada Ltd v Pfizer Canada Inc, 2012 SCC 60 is a leading Supreme Court of Canada decision on the disclosure requirements for a patent in Canada.
Quick Facts Teva Canada Ltd v Pfizer Canada Inc, Hearing: April 18, 2012 Judgment: November 8, 2012 ...
Teva Canada Ltd v Pfizer Canada Inc | |
---|---|
Hearing: April 18, 2012 Judgment: November 8, 2012 | |
Full case name | Teva Canada Limited v Pfizer Canada Inc., Pfizer Inc., Pfizer Ireland Pharmaceuticals, Pfizer Research and Development Company N.V./S.A. and Minister of Health |
Citations | 2012 SCC 60 |
Docket No. | 33951 [1] |
Prior history | APPEAL from Novopharm Limited v. Pfizer Canada Inc., 2010 FCA 242 (23 September 2010), affirming Pfizer Canada Inc. v. Novopharm Limited, 2009 FC 638 (18 June 2009). |
Ruling | Appeal allowed |
Holding | |
The disclosure requirement in Patent Act is evaluated with respect to each invention in the patent, and not necessarily with each individual patent claim. | |
Court membership | |
Chief Justice: Beverley McLachlin Puisne Justices: Louis LeBel, Marie Deschamps, Morris Fish, Rosalie Abella, Marshall Rothstein, Thomas Cromwell, Michael Moldaver, Andromache Karakatsanis | |
Reasons given | |
Unanimous reasons by | LeBel J. |
Fish and Karakatsanis JJ. took no part in the consideration or decision of the case. |
Close